These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7835024)

  • 21. Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.
    Cilursu AM; Goeken J; Olson RR
    Ann Rheum Dis; 1991 Nov; 50(11):817-9. PubMed ID: 1772299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use.
    Varga J; Griffin R; Newman JH; Jimenez SA
    J Rheumatol; 1991 Feb; 18(2):259-63. PubMed ID: 2023221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Demyelinating nervous lesions in myalgia-eosinophilia syndrome induced by L Tryptophan].
    Labauge P; Moulonguet A; Penaud D; Lessana-Leibowitch M; Kahn MF; Said G
    Rev Neurol (Paris); 1993; 149(4):278-82. PubMed ID: 8235226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible lansoprazole-induced eosinophilic syndrome.
    Smith JD; Chang KL; Gums JG
    Ann Pharmacother; 1998 Feb; 32(2):196-200. PubMed ID: 9496405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
    Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
    Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Eosinophilic myalgia from L-tryptophan].
    Hardelin D; Saviuc P; Mallaret M; Brousse P; Danel V
    J Toxicol Clin Exp; 1990 Oct; 10(6):409-12. PubMed ID: 2130184
    [No Abstract]   [Full Text] [Related]  

  • 28. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
    Varga J; Jimenez SA; Uitto J
    J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilia-myalgia syndrome. A clinical case series of 21 patients. New Mexico Eosinophilia-Myalgia Syndrome Study Group.
    Philen RM; Eidson M; Kilbourne EM; Sewell CM; Voorhees R
    Arch Intern Med; 1991 Mar; 151(3):533-7. PubMed ID: 2001136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
    Varga J; Uitto J; Jimenez SA
    Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of patients with diffuse fasciitis and eosinophilia associated with L-tryptophan ingestion.
    Beko E; Pervaiz S; Nanda V; Dhawan S
    Cutis; 1993 Apr; 51(4):266-70. PubMed ID: 8477608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eosinophilia-myalgia syndrome in association with L-tryptophan ingestion.
    Gresh JP; Vasey FB; Espinoza LR; Adelman HM; Germain BF
    J Rheumatol; 1990 Nov; 17(11):1557-8. PubMed ID: 2273503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome.
    Milburn DS; Myers CW
    DICP; 1991 Nov; 25(11):1259-62. PubMed ID: 1763543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central and peripheral nervous system involvement in the L-tryptophan associated eosinophilia myalgia syndrome.
    Tolander LM; Bamford CR
    Int J Neurosci; 1991 Nov; 61(1-2):69-75. PubMed ID: 1809736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
    Keating JP; Wardill K; Viggiano J
    N Z Med J; 1992 Aug; 105(939):317. PubMed ID: 1386918
    [No Abstract]   [Full Text] [Related]  

  • 39. L-tryptophan and eosinophilia-myalgia syndrome.
    Shapiro S
    Lancet; 1994 Apr; 343(8904):1035-7. PubMed ID: 7909063
    [No Abstract]   [Full Text] [Related]  

  • 40. L-tryptophan and eosinophilia-myalgia syndrome.
    Shapiro S
    Lancet; 1994 Sep; 344(8925):817-9. PubMed ID: 7916094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.